[Expression of enhancer of zesle homolog 2 and phosphatase and tension homolog and its clinicopathological significance in benign and malignant lesion of gallbladder].
OBJECTIVE
To examine the expressive level of enhancer of zesle homolog 2 (EZH2) and phosphatase and tension homolog (PTEN), and to explore its clinicopathological significance in benign and malignant lesion of gallbladder.


METHODS
EnVision immunohistochemical method was used to detect the expressive levels of EZH2 and PTEN in routinely paraffin-embedded sections in the resected specimens of gallbladder adenocarcinoma (n = 108), peritumoral tissues (n = 46), adenomatous polyp(n = 15), and chronic cholecystitis (n = 35).


RESULTS
The positive rate of EZH2 was significantly higher in gallbladder adenocarcinoma than that in peritumoral tissues (chi(2) = 24.49, P < 0.01), adenomatous polyp(chi(2) = 11.68, P < 0.01), and chronic cholecystitis (chi(2) = 31.62, P < 0.01). The benign lesions in the positive cases of EZH2 and (or) the negative ones of PTEN showed the moderately- or severely- atypical hyperplasia of gallbladder epithelium. The positive rate of PTEN was significantly lower in gallbladder adenocarcinoma than that in peritumoral tissues(n = 20.20, P < 0.01), adenomatous polyp(chi(2)=10.81, P<0.01), and chronic cholecystitis (n = 29.83, P < 0.01).The positive rates of EZH2 were significantly lower in the highly-differentiated adenocarcinoma, the maximal diameter of mass < 2 cm, non-metastasis of lymphnodes, and non-infiltration of regional tissues than those in the moderately or low-differentiated adenocarcinoma, the maximal diameter > or = 2 cm, metastasis of lymphnode, and infiltration of regional tissues (P < 0.05 or P < 0.01). High inconsistency was found between the expression of EZH2 and PTEN in gallbladder adenocarcinoma (P < 0.05).


CONCLUSIONS
Expression of EZH2 and/or PTEN might be important biological markers in the carcinogenesis, progression, biological behaviors and prognosis of gallbladder adenocarcinoma.
Liu
Dong-Cai
DC
Department of Geriatric Surgery , Second Xiangya Hospital, Central South University, Changsha 410011, China.
Yang
Zhu-Lin
ZL
Yang
Le-Ping
LP
D000230:Adenocarcinoma / Q000235:genetics / Q000473:pathology; D000328:Adult; D014408:Biomarkers, Tumor; D004268:DNA-Binding Proteins / Q000096:biosynthesis*; D000071221:Enhancer of Zeste Homolog 2 Protein; D005260:Female; D005706:Gallbladder Neoplasms / Q000235:genetics* / Q000378:metabolism; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D008297:Male; D008875:Middle Aged; D051059:PTEN Phosphohydrolase / Q000096:biosynthesis*; D063151:Polycomb Repressive Complex 2; D011379:Prognosis; D014157:Transcription Factors / Q000096:biosynthesis*
D014408:Biomarkers, Tumor; D004268:DNA-Binding Proteins; D014157:Transcription Factors; C498409:EZH2 protein, human; D000071221:Enhancer of Zeste Homolog 2 Protein; D063151:Polycomb Repressive Complex 2; D051059:PTEN Phosphohydrolase; C494929:PTEN protein, human